Program
RXR-alpha Variant-targeting Agent NM6603
Its studies are mostly in Neoplasms, led by NucMito Pharmaceuticals.
Furthest: phase 1, since Sep 5, 20232 company-led studies, 1 open or runningNext primary completion: Nov 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| NucMito Pharmaceuticals | 21 open or running | phase 1since Sep 5, 2023 | Sep 5, 2023 | Nov 2026phase 1 · NCT07292038 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 5, 2023First study: phase 1 study in NeoplasmsFirst studyNCT06046066 · 17 enrolled · United States
- Nov 17, 2025Phase 1 study in NeoplasmsNCT07292038 · 30 planned · China
Ahead
- Nov 2026Primary completion: phase 1 study in NeoplasmsNCT07292038
TargetBeta
RXRA →read by rule
“An orally bioavailable small molecule agent that targets retinoid X receptor alpha (RXR-alpha; RXRA) variant, ”NCIt, by rule
Other programs on RXRA
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| AGN 194204rule | io-therapeutics | phase 2 | 5 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07292038Neoplasms · China | 1 | Recruiting | Nov 2026 | 30 |
| NCT06046066Neoplasms · United States | 1 | Terminated | Apr 25, 2025 | 17 |
How it is read
Names in the registry
- “NM6603”, 2 entries
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.